Moderna, Inc. (MRNA) shares fell 11.5% in early trading Wednesday after the company announced that the FDA had issued a refusal-to-file letter for its mRNA flu vaccine application, citing concerns related to the trial design. The company is seeking an urgent meeting with the agency and has already submitted applications in Europe, Canada, and Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.